DENTSPLY SIRONA Inc. — Form 8-K/A
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 28/100
What the filing says
DENTSPLY SIRONA reported Q2 2026 net sales of $898M (down 4.1% YoY from $936M); GAAP diluted EPS $0.18 vs. loss of $0.22 in Q2 2025; adjusted EPS flat at $0.52. Company repurchased 1.3M shares for ~$12M. Expanded partnership with Medline Sinclair for Canada distribution. Reiterates full-year 2026 guidance: net sales $3.5B–$3.6B, adjusted EPS $1.40–$1.50. Operating cash flow improved to $99M (vs. $48M prior year) partly due to ~$44M tariff refunds.
Why this rating
Modest revenue decline, flat adjusted EPS, and normal quarterly disclosure. Small share buyback ($12M ≈ 0.4% of market cap) routine. Partnership expansion is routine business development. No material guidance change, impairment, or strategic shift.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.